Arcoxia licensed for pain following dental surgery

Arcoxia (etoricoxib) has been approved for the short-term treatment of moderate pain associated with dental surgery.

As well as it's use following dental surgery, etoricoxib is also licensed for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis | SCIENCE PHOTO LIBRARY
As well as it's use following dental surgery, etoricoxib is also licensed for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis | SCIENCE PHOTO LIBRARY

The recommended dose of etoricoxib is 90mg once daily for a maximum of 3 days. Additional postoperative analgesia can be prescribed if required.

No dosage adjustment is necessary for the elderly. However, etoricoxib is contraindicated in patients with creatinine clearance <30ml/min and dose reduction is required for patients with hepatic impairment.

View Arcoxia drug record

Further information: Merck Sharp & Dohme Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases